Academic Highlights: Guidelines for the Use of Long-Acting Injectable Atypical Antipsychotics. [CME]
J Clin Psychiatry 2004;65(1):120-131
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
John M. Kane, M.D., opened the meeting by addressing the need for guidelines on the use of long-acting injectable atypical antipsychotics. For about 40 years, some of the conventional antipsychotics, which include chlorpromazine, fluphenazine, and haloperidol, have been available in long-acting injectable formulations for the long-term treatment of schizophrenia. In 1989, clozapine became the first atypical antipsychotic to be approved by the U.S. Food and Drug Administration (FDA). However, until recently, none of the atypical antipsychotics which also include aripiprazole, olanzapine, quetiapine, risperidone, andziprasidonehave been available in injectable formulations.